Factor This Power Engineering
Live Events
DTECH® Events
POWERGEN™
INFOCAST Events
Calendar
Webinars
Podcasts
Contribute Content
Solar
Community
Residential
Utility Scale
Wind Power
Offshore
Turbines & Equipment
Power Grid
Distribution
Grid Modernization
Microgrids
Outage Management
Smart Grids
Transmission
Hydropower
Dams & Civil Structures
Small Hydropower
Technology & Equipment
Tidal & Wave Energy
Energy Storage
Battery
Long Duration
Pumped Storage
Business
Finance
Policy & Regulation
Project Development
Tariffs
Electric Vehicles
EV Charging
Vehicle to Grid
Subscribe
Solar
Community
Residential
Utility Scale
Wind Power
Offshore
Turbines & Equipment
Power Grid
Distribution
Grid Modernization
Microgrids
Outage Management
Transmission
Smart Grids
Hydropower
Dams & Civil Structures
Small Hydro
Technology & Equipment
Tidal & Wave Energy
Energy Storage
Battery
Long Duration
Pumped Storage
Business
Finance
Policy & Regulation
Electric Vehicles
EV Charging
Vehicle to Grid
Factor This: Power Engineering
Live Events
DISTRIBUTECH®
POWERGEN™
INFOCAST Events
Podcasts
Webinars
Calendar
Contribute Content
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Hydroworld Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Halozyme Therapeutics, Inc. - Common Stock
(NQ:
HALO
)
67.17
-2.03 (-2.94%)
Streaming Delayed Price
Updated: 11:37 AM EDT, May 15, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Halozyme Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
↗
March 11, 2025
HALOZYME THERAPEUTICS INC has a stellar value proposition. NASDAQ:HALO not only scores well in profitability, solvency, and liquidity but also maintains a very reasonable price point.
Via
Chartmill
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Technical Analysis observations.
↗
March 06, 2025
Exploring HALOZYME THERAPEUTICS INC's Technical Signals and Breakout Potential: A technical analysis of HALOZYME THERAPEUTICS INC (NASDAQ:HALO) shows it may be setting up for a breakout.
Via
Chartmill
NASDAQ:HALO: a strong growth stock preparing for the next leg up?.
↗
February 26, 2025
Based on a technical and fundamental analysis of NASDAQ:HALO we conclude: HALOZYME THERAPEUTICS INC (NASDAQ:HALO)—A High-Growth Stock Gearing Up for Its Next Upward Move.
Via
Chartmill
Assessing Halozyme Therapeutics: Insights From 9 Financial Analysts
↗
February 20, 2025
Via
Benzinga
NASDAQ:HALO is not too expensive for the growth it is showing.
↗
February 17, 2025
HALOZYME THERAPEUTICS INC could be undervalued. NASDAQ:HALO is scoring impressively in terms of growth while demonstrating strong financials. On top of that, it remains attractively priced.
Via
Chartmill
NASDAQ:HALO appears to be flying under the radar despite its strong fundamentals.
↗
February 17, 2025
Discover HALOZYME THERAPEUTICS INC, an undervalued stock. NASDAQ:HALO showcases solid financial health and profitability while maintaining an appealing valuation.
Via
Chartmill
Demystifying Halozyme Therapeutics: Insights From 8 Analyst Reviews
↗
February 04, 2025
Via
Benzinga
Analyst Expectations For Halozyme Therapeutics's Future
↗
January 13, 2025
Via
Benzinga
9 Analysts Have This To Say About Halozyme Therapeutics
↗
December 18, 2024
Via
Benzinga
Earnings Scheduled For February 18, 2025
↗
February 18, 2025
Via
Benzinga
Is NASDAQ:HALO on the Verge of a Major Breakout as a Strong Growth Stock?
↗
December 18, 2024
Why HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Is a Promising High-Growth Stock in the Midst of Consolidation.
Via
Chartmill
Looking for growth without the hefty price tag? Consider NASDAQ:HALO.
↗
December 16, 2024
NASDAQ:HALO, a growth stock which is not overvalued.
Via
Chartmill
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is a candidate for high growth investors. Here's why.
↗
February 03, 2025
A fundamental and technical analysis of (NASDAQ:HALO): HALOZYME THERAPEUTICS INC (NASDAQ:HALO) may be suited for high growth investing, we'll explore why in this article.
Via
Chartmill
NASDAQ:HALO—A High-Growth Stock Gearing Up for Its Next Upward Move.
↗
February 03, 2025
Based on fundamental and technical analysis of NASDAQ:HALO we ask: Why HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Is a Standout High-Growth Stock in a Consolidation Phase.
Via
Chartmill
In the world of growth stocks, NASDAQ:HALO shines as a value proposition.
↗
January 27, 2025
HALOZYME THERAPEUTICS INC was identified as an affordable growth stock. NASDAQ:HALO is showing great growth, but also scores well on profitability. At the same time it seems to be priced reasonably.
Via
Chartmill
In a market where value is scarce, NASDAQ:HALO offers a refreshing opportunity with its solid fundamentals.
↗
January 24, 2025
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
Via
Chartmill
BeiGene Stock Meets 80-Plus RS Rating Benchmark
↗
January 15, 2025
One key metric to look for in a stock is an 80-plus Relative Strength Rating. BeiGene stock just hit that mark, with a jump to 84 Wednesday.
Via
Investor's Business Daily
BridgeBio Pharma Stock Earns 87 RS Rating
↗
January 14, 2025
BridgeBio Pharma stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, with an increase from 64 to 87.
Via
Investor's Business Daily
(HALO) - Analyzing Halozyme Therapeutics's Short Interest
↗
December 11, 2024
Via
Benzinga
Breaking Down Halozyme Therapeutics: 10 Analysts Share Their Views
↗
November 20, 2024
Via
Benzinga
Looking Into Halozyme Therapeutics's Recent Short Interest
↗
November 05, 2024
Via
Benzinga
SpringWorks Therapeutics Stock Gets A RS Rating Lift
↗
January 08, 2025
The Relative Strength (RS) Rating for SpringWorks Therapeutics stock entered a higher percentile Wednesday, as it got a lift from 62 to 76.
Via
Investor's Business Daily
Despite its growth, NASDAQ:HALO remains within the realm of affordability.
↗
January 06, 2025
Don't overlook HALOZYME THERAPEUTICS INC (NASDAQ:HALO)—a stock with solid growth prospects and a reasonable valuation.
Via
Chartmill
In a market where value is scarce, NASDAQ:HALO offers a refreshing opportunity with its solid fundamentals.
↗
January 03, 2025
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is an undervalued gem with solid fundamentals.
Via
Chartmill
In a market where value is scarce, NASDAQ:HALO offers a refreshing opportunity with its solid fundamentals.
↗
December 13, 2024
For those who appreciate value investing, HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is a compelling option with its solid fundamentals.
Via
Chartmill
Halozyme Withdraws Evotec Bid After Rebuff, Reaffirms Strong Growth Outlook
↗
November 22, 2024
Halozyme stock rises after withdrawing its €2B acquisition offer for Evotec, while reaffirming strong growth outlook for 2024.
Via
Benzinga
While growth is established for NASDAQ:HALO, the stock's valuation remains reasonable.
↗
November 22, 2024
NASDAQ:HALO stands out as a growth opportunity that won't break the bank.
Via
Chartmill
NASDAQ:HALO is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
↗
November 22, 2024
Despite its impressive fundamentals, HALOZYME THERAPEUTICS INC (NASDAQ:HALO) remains undervalued.
Via
Chartmill
Large Pharma Partner Halozyme Therapeutics Offers To Acquire Germany-Based Evotec For ~$2 Billion
↗
November 15, 2024
Halozyme offers to acquire Evotec for €11.00 per share, boosting Evotec's value to €2 billion. The merger aims to enhance Halozyme's revenue growth and portfolio.
Via
Benzinga
Amazon Posts Upbeat Results, Joins Cardinal Health, Waters, Atlassian, Charter Communications, MasTec And Other Big Stocks Moving Higher On Friday
↗
November 01, 2024
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
